UDP glucuronosyltransferase family 2 member B26, pseudogeneGenealiases: []
Q-omics provides the consensus-scored UGT2B26P profile across patient tissues and cancer cell-line models. UGT2B26P expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, UGT2B26P is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, UGT2B26P RNA expression shows 10,531 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight BLCA, KICH, and KIRP as cancer lineages where UGT2B26P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UGT2B26P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UGT2B26P survival associations across molecular data types. UGT2B26P RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UGT2B26P RNA expression–survival associations across cancer types. High UGT2B26P expression shows unfavorable associations in CHOL, LUAD and LGG, but favorable associations in BLCA, LUSC and READ. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for UGT2B26P RNA expression.
This table summarizes UGT2B26P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for UGT2B26P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UGT2B26P shows lower tumor expression in KICH and PRAD and higher tumor expression in LIHC, KIRC, STAD and COAD. The KICH box plot shows higher UGT2B26P RNA expression in normal versus tumor tissue (log2 FC = −1.920, t-test p < 0.001).
This table shows molecular features associated with UGT2B26P in patient tissues and cancer cell lines. In patient samples, UGT2B26P shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
